{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:27:32Z","timestamp":1789158452759,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Daratumumab combined with bortezomib, thalidomide, and dexamethasone (Dara-VTD) is a highly effective induction therapy for newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplantation (ASCT). However, its impact on stem cell mobilization requires a critical evaluation. This study examines the effects of Dara-VTD on stem cell mobilization and collection outcomes. A multicenter retrospective study included 81 consecutive NDMM patients treated with Dara-VTD (from November 2021 to June 2023). Data on stem cell mobilization and collection were compared with 93 historical VTD patients. Mobilization regimens included cyclophosphamide (CTX), vinorelbine\u2009+\u2009CTX, and chemotherapy-free approaches, with plerixafor used as rescue therapy. Mobilization success was evaluated by CD34\u2009+\u2009cell yield, additional agent use, and leukapheresis sessions required. The median CD34\u2009+\u2009yield in the Dara-VTD group was 5.1 million cells\/kg, with 96.3% of patients achieving\u2009&gt;\u20092\u2009\u00d7\u200910^6 cells\/kg of body weight. Plerixafor use was significantly higher in the Dara-VTD group (56.2%) compared to VTD (4.3%), and CTX-based regimens showed superior mobilization efficacy (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01). Engraftment was faster in the Dara-VTD group, with median neutrophil and platelet recovery at 11 and 13\u00a0days, compared to 12 and 17\u00a0days in the VTD group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Dara-VTD maintains the feasibility of ASCT, with comparable stem cell mobilization and collection outcomes to VTD. Mobilization success is influenced by individualized strategies, with CTX and plerixafor playing key roles in optimizing stem cell yield. Despite the challenges posed by daratumumab, stem cell mobilization remains effective, and Dara-VTD does not compromise the transplant process.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06581-x","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:53:49Z","timestamp":1757058829000},"page":"5371-5378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-231X","authenticated-orcid":false,"given":"Roberta","family":"Della Pepa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-4147","authenticated-orcid":false,"given":"Salvatore","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4005-8592","authenticated-orcid":false,"given":"Stefano","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2714-5109","authenticated-orcid":false,"given":"Novella","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7148-7122","authenticated-orcid":false,"given":"Aldo","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Avilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4371-5063","authenticated-orcid":false,"given":"Marialucia","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7194-7246","authenticated-orcid":false,"given":"Rosa","family":"Rosamilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-0729","authenticated-orcid":false,"given":"Fabio","family":"Trastulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2590-0529","authenticated-orcid":false,"given":"Danilo","family":"De Novellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3990-120X","authenticated-orcid":false,"given":"Raffaele","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4921-1081","authenticated-orcid":false,"given":"Denise","family":"Morini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8181-5600","authenticated-orcid":false,"given":"Lorenzo","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9280-2023","authenticated-orcid":false,"given":"Laura","family":"De Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1323-9276","authenticated-orcid":false,"given":"Roberta","family":"Spisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5861-8984","authenticated-orcid":false,"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5633-4657","authenticated-orcid":false,"given":"Catello","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0136-7686","authenticated-orcid":false,"given":"Alessandra","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-947X","authenticated-orcid":false,"given":"Mario","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2563-4125","authenticated-orcid":false,"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"issue":"10192","key":"6581_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394(10192):29\u201338","journal-title":"Lancet"},{"issue":"1","key":"6581_CR2","doi-asserted-by":"publisher","first-page":"e2024041","DOI":"10.4084\/MJHID.2024.041","volume":"16","author":"M Passucci","year":"2024","unstructured":"Passucci M et al (2024) Impact of Daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-centre study. Mediterr J Hematol Infect Dis 16(1):e2024041","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"6581_CR3","doi-asserted-by":"publisher","first-page":"e2024049","DOI":"10.4084\/MJHID.2024.049","volume":"16","author":"G Cavallaro","year":"2024","unstructured":"Cavallaro G et al (2024) Impact of the addition of Daratumumab to the standard bortezomib-thalidomide-dexamethasone regimen on hematopoietic stem cell mobilization and collection, post-transplant engraftment and infectious complications: a case-control multicentre real-life analysis. Mediterr J Hematol Infect Dis 16(1):e2024049","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"12","key":"6581_CR4","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.3324\/haematol.2023.283452","volume":"108","author":"C Liberatore","year":"2023","unstructured":"Liberatore C et al (2023) Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma. Haematologica 108(12):3502\u20133505","journal-title":"Haematologica"},{"issue":"6","key":"6581_CR5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41409-024-02260-z","volume":"59","author":"F Fazio","year":"2024","unstructured":"Fazio F et al (2024) Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the multiple myeloma group. Bone Marrow Transplant 59(6):896\u2013898","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"6581_CR6","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM et al (2020) Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136(8):936\u2013945","journal-title":"Blood"},{"issue":"2","key":"6581_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41409-019-0676-0","volume":"55","author":"C Morris","year":"2020","unstructured":"Morris C et al (2020) Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. Bone Marrow Transplant 55(2):356\u2013366","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"6581_CR8","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/leu.2009.127","volume":"23","author":"S Giralt","year":"2009","unstructured":"Giralt S et al (2009) International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23(10):1904\u20131912","journal-title":"Leukemia"},{"issue":"3","key":"6581_CR9","first-page":"176","volume":"30","author":"SA Tuchman","year":"2015","unstructured":"Tuchman SA et al (2015) Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J ClinApher 30(3):176\u2013182","journal-title":"J ClinApher"},{"issue":"1","key":"6581_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/bmt.2010.54","volume":"46","author":"RF Duarte","year":"2011","unstructured":"Duarte RF et al (2011) Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 46(1):52\u201358","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"6581_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41409-020-01007-w","volume":"56","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N et al (2021) Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. Bone Marrow Transplant 56(1):210\u2013217","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"6581_CR12","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.bbmt.2020.04.016","volume":"26","author":"L Garderet","year":"2020","unstructured":"Garderet L et al (2020) Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? A review from the chronic malignancies working party of the EBMT. Biol Blood Marrow Transplant 26(9):1559\u20131566","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"6581_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jtct.2024.06.030","volume":"30","author":"CP Venner","year":"2024","unstructured":"Venner CP et al (2024) Tandem autologous stem cell transplantation does not benefit high-risk myeloma patients in the maintenance era: real-world results from the Canadian myeloma research group database. Transplant Cell Ther 30(9):889\u2013901","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"6581_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/cells13100853","volume":"13","author":"S Rocchi","year":"2024","unstructured":"Rocchi S et al (2024) Multiple myeloma: the role of autologous stem cell transplantation in the era of immunotherapy. Cells 13(10):853. https:\/\/doi.org\/10.3390\/cells13100853","journal-title":"Cells"},{"issue":"8","key":"6581_CR15","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","volume":"25","author":"P Moreau","year":"2024","unstructured":"Moreau P et al (2024) Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol 25(8):1003\u20131014","journal-title":"Lancet Oncol"},{"key":"6581_CR16","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3389\/fimmu.2018.01228","volume":"9","author":"T Plesner","year":"2018","unstructured":"Plesner T, Krejcik J (2018) Daratumumab for the treatment of multiple myeloma. Front Immunol 9:1228","journal-title":"Front Immunol"},{"issue":"3","key":"6581_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J et al (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3):384\u2013394","journal-title":"Blood"},{"issue":"24","key":"6581_CR18","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","volume":"23","author":"J Krejcik","year":"2017","unstructured":"Krejcik J et al (2017) Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab. Clin Cancer Res 23(24):7498\u20137511","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6581_CR19","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/bjh.19141","volume":"204","author":"O Venglar","year":"2024","unstructured":"Venglar O et al (2024) Insight into the mechanism of CD34(+) cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy. Br J Haematol 204(4):1439\u20131449","journal-title":"Br J Haematol"},{"issue":"2","key":"6581_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.transci.2016.11.005","volume":"56","author":"P Ataca Atilla","year":"2017","unstructured":"Ataca Atilla P, BakanayOzturk SM, Demirer T (2017) How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation? Transfus Apher Sci 56(2):190\u2013198","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"6581_CR21","first-page":"1141","volume":"18","author":"X Yang","year":"2019","unstructured":"Yang X et al (2019) Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: a systematic review and meta-analysis. Exp Ther Med 18(2):1141\u20131148","journal-title":"Exp Ther Med"},{"issue":"10","key":"6581_CR22","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1007\/s00277-024-05933-3","volume":"103","author":"V Strafella","year":"2024","unstructured":"Strafella V et al (2024) Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy. Ann Hematol 103(10):4345\u20134347.\u00a0https:\/\/doi.org\/10.1007\/s00277-024-05933-3","journal-title":"Ann Hematol"},{"issue":"4","key":"6581_CR23","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1007\/s00277-025-06372-4","volume":"104","author":"S Kwon","year":"2025","unstructured":"Kwon S et al (2025) Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma. Ann Hematol 104(4):2297\u20132304","journal-title":"Ann Hematol"},{"issue":"3","key":"6581_CR24","doi-asserted-by":"publisher","first-page":"174 e1","DOI":"10.1016\/j.jtct.2022.11.029","volume":"29","author":"S Chhabra","year":"2023","unstructured":"Chhabra S et al (2023) Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. Transplant Cell Ther 29(3):174 e1-174 e10","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"6581_CR25","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3390\/cancers16101854","volume":"16","author":"J Mehl","year":"2024","unstructured":"Mehl J et al (2024) Daratumumab during myeloma induction therapy is associated with impaired stem cell mobilization and prolonged post-transplant hematologic recovery. Cancers (Basel) 16(10):1854. https:\/\/doi.org\/10.3390\/cancers16101854","journal-title":"Cancers (Basel)"},{"issue":"5","key":"6581_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000529691","volume":"50","author":"S Sauer","year":"2023","unstructured":"Sauer S et al (2023) Autologous stem cell collection after daratumumab, bortezomib, thalidomide, and dexamethasone versus bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma. Transfus Med Hemother 50(5):371\u2013381","journal-title":"Transfus Med Hemother"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06581-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06581-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06581-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:19:28Z","timestamp":1763194768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06581-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6581"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06581-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients received informed consent obtained in accordance with the Declaration of Helsinki (World Medical Association 2013) and protocol approved by local ethic committee (Ethics Committee \u201cCampania 3\u201d, Naples, Italy; prot. no. 50\/2025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}